GlassScriptPhysician profile
Lauren Tezak
NPI 1508225467
$4,566.95
in general payments reported to CMS, 2019-2025
23 companies · $299 in 2025
The $299 reported for 2025 was more than what a typical Acute Care (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $407 · 2022: $1,040 · 2023: $1,474 · 2024: $1,347 · 2025: $299.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,120.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,788.97 | 2022-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems |
| La Jolla Pharmaceutical Company | $442.71 | 2021-2025 | Zevtera, Giapreza |
| Abbvie INC. | $225.06 | 2022-2023 | |
| Abiomed | $134.62 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $125.17 | 2023 | Uptravi, Opsumit |
| Astrazeneca Pharmaceuticals LP | $125.04 | 2022 | |
| Sobi, INC | $125.00 | 2024 | |
| Gilead Sciences, INC. | $125.00 | 2024 | |
| Xeris Pharmaceuticals, INC. | $122.33 | 2024 | Gvoke Hypopen |
| Mallinckrodt Hospital Products INC. | $122.17 | 2024 | Terlivaz |
| Alexion Pharmaceuticals, INC. | $121.49 | 2021 | |
| Janssen Pharmaceuticals, INC | $120.14 | 2021 | |
| Genzyme Corporation | $119.02 | 2023 | |
| Inspire Medical Systems, INC. | $118.62 | 2023 | Inspire |
| Edwards Lifesciences Corporation | $100.92 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $99.84 | 2022 | |
| Glaxosmithkline, LLC. | $98.88 | 2022 | |
| Amgen INC. | $97.24 | 2024 | Uplizna |
| Mylan Specialty L.P. | $93.53 | 2023 | Yupelri |
| Genentech USA, INC. | $90.61 | 2024 | Xolair |
| Fisher & Paykel Healthcare INC | $72.11 | 2021 | |
| Sk Life Science, INC. | $60.65 | 2022 | |
| Medtronic, INC. | $37.83 | 2023 | Intellis Adaptivestim |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Tezak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.